COMPANY:

Lunit

"Lunit...today announced the presentation of three studies at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place November 5-9 in Maryland, U.S. The findings highlight how Lunit’s AI-powered digital pathology technologies—Lunit SCOPE IO® and Lunit SCOPE® uIHC—can advance precision oncology by uncovering predictive immune signatures and guiding antibody-based drug development."

"Lunit...today announced that its solutions have been selected as the exclusive AI tools for the breast cancer screening program of the Valencian Community, one of Spain’s largest and most progressive healthcare regions...The contract covers the implementation of Lunit INSIGHT MMG and Lunit INSIGHT DBT across the region and marks the company’s largest European project to date."

"Akumin...has selected Lunit INSIGHT DBT™, a leading AI solution for early breast cancer detection. The decision marks a key step in Akumin’s plans to integrate advanced technologies that elevate care delivery and expand patient access to precision diagnostics. "

"Lunit...today announced major milestones in the United States, one year after its acquisition of Volpara Health Technologies. Since acquiring Volpara, Lunit has significantly expanded its presence across North America. By June 2025, Lunit’s AI solutions for digital breast tomosynthesis (Lunit INSIGHT DBT) and mammography analysis (Lunit INSIGHT MMG) will be deployed at over 200 imaging centers and hospitals across the U.S., with approximately 350 to 400 radiologists utilizing its technology."

P=NA | N=29 | "One of the featured studies, conducted with Japan’s National Cancer Center Hospital East (NCCE), evaluated HER2 expression in biliary tract cancer (BTC) patients using Lunit’s AI-powered analyzer. The resulting AI scores showed strong agreement with pathologist-assigned IHC scores in a 288-patient screening cohort. Among 29 patients treated with trastuzumab deruxtecan (T-DXd), those with higher levels of HER2-intense tumor cells achieved a higher objective response rate (ORR) of 50%, along with significantly longer progression-free survival and overall survival. The study also found that AI-derived 'membrane specificity' helped identify additional responders who achieved a 50% ORR and improved survival."

"Lunit...today announced the publication of a new study in Radiology (RSNA’s flagship journal), highlighting how radiologists interact with AI in real-world breast cancer screening...The study, based on the prospective ScreenTrustCAD trial, is the first large-scale, population-based trial to evaluate how radiologists interact with AI in an operational breast cancer screening setting. Conducted at Capio St Göran Hospital in Stockholm, Sweden, the trial enrolled about 55,000 women and implemented Lunit INSIGHT MMG as an independent third reader alongside two radiologists."

"Lunit...today announced a collaboration with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), to explore innovative applications of AI in cancer research. This collaboration aims to advance research into the tumor microenvironment and immune phenotyping, analyzing NCI data to uncover insights that could drive personalized cancer care."

"Lunit...today announced the publication of a groundbreaking prospective study in Nature Communications validating the real-world effectiveness of AI-powered mammography screening in South Korea’s national breast cancer screening program. Conducted as the world’s first large-scale, multicenter prospective study in a single-reading setting, the research underscores how AI-assisted mammography interpretation significantly improves breast cancer detection rates without increasing recall rates."

"Lunit...today announced a landmark achievement at the European Congress of Radiology (ECR) 2025, taking place in Vienna, Austria, from February 26 to March 2. With 15 research abstracts accepted and 13 designated as oral presentations, this year’s participation marks Lunit’s largest and most influential presence at ECR to date. The high acceptance rate underscores Lunit’s growing leadership in AI-driven radiology, with its research recognized as highly relevant to the future of cancer screening and detection. Among the featured studies, two highlight groundbreaking findings that further solidify Lunit INSIGHT MMG as a clinically proven tool in mammography interpretation and workflow optimization. "

"Lunit...has entered into a partnership with the Society for Immunotherapy of Cancer (SITC). This collaboration will launch the 'Lunit Research Program' for SITC members, granting access to Lunit SCOPE® IO for quantitative immune phenotyping and tumor microenvironment (TME) analysis from H&E whole slide images (WSIs)."

"At this year's RSNA 2024 Annual Meeting, Lunit...and Volpara Health, a Lunit company and a global leader in mammography AI for the early detection of cancer, announced their unified vision, focusing on a comprehensive Ecosystem for early cancer detection, cancer risk prediction, and autonomous AI for enhanced clinical workflows."

"Lunit...unveiled follow-up findings from the groundbreaking ScreenTrustCAD trial at the Radiological Society of North America (RSNA) 2024 Annual Meeting. This study, conducted at Capio S:t Göran Hospital in Sweden, reinforces the real-world impact of Lunit INSIGHT MMG, which has successfully replaced one of the two human readers in the hospital’s double-reading breast cancer screening protocol."